Italian OTC approval for ActiPatch

November 2008
Medical Device Daily;11/4/2008, Vol. 12 Issue 215, p8
The article reports on the approval received by BioElectronics from the Italian Ministry of Health in November 2008 for the over-the-counter (OTC) sales of its ActiPatch drug-free anti-inflammatory patch throughout Italy. Features of ActiPatch are described. Also noted is the increasing market demand for the patch in the country.


Related Articles

  • Product UPDATE.  // Pharmaceutical Executive;Nov2003, Vol. 23 Issue 11, p36 

    Presents news and developments concerning several approved drugs compiled as of November 2003. Approval of anti-inflammatory drug, Prexige from Novartis in Europe; Development and approval of Inspra, by Pfizer which is effective in improving survival rates among heart-attack patients; Approval...

  • BioElectronics in expansion pact with its provider TSS Medical.  // Medical Device Daily;12/5/2007, Vol. 11 Issue 220, p5 

    The article reports on the agreement of BioElectronics to expand with Tecnica Scientifica Service (TSS) Medical its medical provider distributor into the retail pharmacies in Italy. TSS has acquired 10,000 units of the ActiPatch product to initiate the retail product launch in the country....

  • ActiPatch cleared for sale in Australia.  // Medical Device Daily;10/11/2007, Vol. 11 Issue 195, p8 

    The article reports that the sale of ActiPatch in Australia has been approved by the Australian Therapeutic Goods Administration. ActiPatch, a drug-free, anti-inflammatory patch with an embedded battery-operated microchip that delivers weeks of continuous pulsed therapy to reduce soft-tissue...

  • Eye on the Literature.  // Formulary;Jan2004, Vol. 39 Issue 1, p18 

    Reveals information on drug studies of interest to drug decision-makers in the U.S. Effect of non-stereoidal anti-inflammatory agents use on aspirin efficacy in myocardial infarction; Efficacy of combination docetaxel/platinum in treating non-small cell lung cancer; Reduction of breast cancer...

  • Summary of the 31st Meeting of the Food and Drug Administration Gastrointestinal Drugs Advisory Committee December 8-9,1986. Lewis, James H. // American Journal of Gastroenterology;May1987, Vol. 82 Issue 5, p443 

    Highlights the 31st Meeting of the U.S. Food and Drug Administration Gastrointestinal Drugs Advisory Committee in Bethesda, Maryland in December 1986. Recommended approval for loperamide hydrochloride oral liquid; Therapeutic use for ethanolamine oleate; Discussion on the antiinflammatory...

  • Naproxcinod Meets Endpoints in Third Phase III Arthritis Trial. Morrison, Trista // BioWorld Today;11/25/2008, Vol. 19 Issue 230, p4 

    The article discusses the results of the pivotal Phase III trial of anti-inflammatory drug naproxcinoid for osteoarthritis. According to the double-blind trial, called Study 303, conducted by NicOx SA, the drug performed well against placebo in patients with osteoarthritis of the hip. A new drug...

  • Two New Drugs Approved for Treatment of Hepatitis C.  // Internal Medicine Alert;6/15/2011 Supplement, p1 

    The article offers updates related to pharmacology in the U.S. which include the new drugs approved by the Food & Drug Administration (FDA) for the treatment of hepatitis C, the risks of nonsteroidal anti-inflammatory drug (NSAID), and FDA's approval of linagliptin for treatment of type 2 diabetes.

  • FDA expands indication for bromfenac use.  // Ophthalmology Times;3/1/2006, Vol. 31 Issue 5, p8 

    The article announces the United States Food and Drug Administration's approval of the supplemental drug application for bromfenac ophthalmic solution from ISTA Pharmaceuticals. Bromfenac is a topical, non-steroidal anti-inflammatory solution, for the treatment of ocular inflammation following...

  • Speak Out. Griffin, Andrew S. // Urology Times;2/1/2005, Vol. 33 Issue 2, p28 

    Presents the views of physicians regarding the withdrawal of rofecoxib by the U.S. Food and Drug Administration from the market and the drug approval process of the Agency. Change in the type of drugs prescribed by physicians; Shortcomings of the Agency in the drug approval process; Risk-benefit...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics